Low-dose total skin electron beam therapy as an effective modality to reduce disease burden in patients with mycosis fungoides: Results of a pooled analysis from 3 phase-II clinical trials

Journal of the American Academy of Dermatology

Volumn 72, Issue 2, 2015, Pages 286-292

  Hoppe, Richard T ^a   Harrison, Cameron ^a   Tavallaee, Mahkam ^a   Bashey, Sameer ^a   Sundram, Uma ^a   Li, Shufeng ^a   Million, Lynn ^a   Dabaja, Bouthaina ^b   Gangar, Pamela ^b   Duvic, Madeleine ^b   Kim, Youn H ^a  

^a STANFORD CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cutaneous lymphoma; Low dose total skin electron beam therapy; Radiotherapy; T cell lymphoma; Total skin electron beam therapy

Indexed keywords

BEXAROTENE; INTERFERON; METHOTREXATE; ROMIDEPSIN; VORINOSTAT;

ACTINIC KERATOSIS; ADULT; AGED; ALOPECIA; ANOREXIA; ARTICLE; BLISTER; CHEILITIS; CLINICAL ARTICLE; EYE SWELLING; FATIGUE; FEMALE; HUMAN; HYPOMAGNESEMIA; LEUKOPENIA; LIMB PAIN; MALE; MOUTH ULCER; MYCOSIS FUNGOIDES; NAIL DISEASE; NAIL RIDGING; PATIENT SAFETY; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; PUVA; RADIATION DERMATITIS; RADIATION DOSE; RADIATION DOSE FRACTIONATION; SCALP PAIN; SKIN INFECTION; SKIN PAIN; SYSTEMIC THERAPY; TOTAL SKIN ELECTRON THERAPY; TREATMENT RESPONSE; VESICULAR RASH; XEROSIS; CANCER STAGING; COST OF ILLNESS; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); RADIODERMATITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RETROSPECTIVE STUDY; SKIN NEOPLASMS; TREATMENT OUTCOME; VERY ELDERLY; WHOLE BODY RADIATION;

ADULT; AGED; AGED, 80 AND OVER; CLINICAL TRIALS, PHASE II AS TOPIC; COST OF ILLNESS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MYCOSIS FUNGOIDES; NEOPLASM STAGING; RADIODERMATITIS; RADIOTHERAPY DOSAGE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; TREATMENT OUTCOME; WHOLE-BODY IRRADIATION;

EID: 84922567743     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2014.10.014     Document Type: Article

References (20)

1. Swerdlow S, Campo E, Harris N, et al. World Health Organization (WHO) classification of tumors of hematopoietic and lymphoid tissues. 4th ed. Lyon: IARC Press; 2008.
2. Criscione V, Weinstock M. Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002. Arch Dermatol. 2007;143:854-859.
3. Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110:1713-1722.
4. AJCC. AJCC cancer staging manual. New York: Springer; 2010.
5. National Comprehensive Cancer Network. Non-Hodgkin's lymphoma (Version 4.2014). http://www.nccn.org/about/nhl.pdf. Accessed November 4, 2014.
6. Kim Y, Liu H, Mraz-Gernhard S, Varghese A, Hoppe R. Long-term outcome of 525 patients with mycosis fungoides and Sézary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol. 2003;139:857-866.
7. Jones G, Hoppe R, Glatstein E. Electron beam treatment for cutaneous T-cell lymphoma. Hematol Oncol Clin North Am. 1995;9:1057-1076.
8. Lo T, Salzman F, Wright K. Dose considerations in total skin electron radiation in mycosis fungoides. Am J Roentgenol. 1979;132:261-263.
9. Hoppe R. Mycosis fungoides: radiation therapy. Dermatol Ther. 2003;16:347-354.
10. Becker M, Hoppe R, Knox S. Multiple courses of high-dose total skin electron beam therapy in the management of mycosis fungoides. Int J Radiat Oncol Biol Phys. 1995;32: 1445-1449.
11. Wilson L, Quiros P, Kolenik S, et al. Additional courses of total skin electron beam therapy in the treatment of patients with recurrent cutaneous T-cell lymphoma. J Am Acad Dermatol. 1996;35:69-73.
12. Harrison C, Young J, Navi D, et al. Revisiting low dose total skin electron beam therapy in mycosis fungoides. Int J Radiat Oncol Biol Phys. 2011;81:e651-e657.
13. Hoppe R, Fuks Z, Bagshaw M. Radiation therapy in the management of cutaneous T-cell lymphoma. Cancer Treat Rep. 1979;63:625-632.
14. Olsen E, Whittaker S, Kim Y, et al. Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organization for Research and Treatment of Cancer. J Clin Oncol. 2011;29:2598-2607.
15. Zackheim H, Kashani-Sabet M, Amin S. Topical corticosteroids for mycosis fungoides: experience in 79 patients. Arch Dermatol. 1998;134:949-954.
16. Kim Y, Martinez G, Varghese A, Hoppe R. Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experience. Arch Dermatol. 2003;139: 165-173.
17. Gathers R, Scherschun L, Malick F, Fivenson D, Lim H. Narrowband UVB phototherapy for early-stage mycosis fungoides. J Am Acad Dermatol. 2002;47:191-197.
18. Duvic M, Martin A, Kim Y, et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol. 2001;137:581-593.
19. Olsen E, Kim Y, Kuzel T, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007;25:3109-3115.
20. Kamstrup M, Lindahl L, Gniadecki R, et al. Low-dose total skin electron beam therapy as a debulking agent for cutaneous T-cell lymphoma: an open-label prospective phase II study. Br J Dermatol. 2011;166:399-404.